- CXCR2+ MDSC are recruited via CXCL5 and CXCL8 to RCC - targeting CXCR2 reduces MDSC numbers and increases T cell infiltration - Combination of CXCR2 blockade and immune-checkpoint inhibition leads to more pronounced tumor growth reduction in murine models. Here, CXCL5 is linked to neoplasm.